Subcutaneous placebo

BIOLOGICAL8 trials

Conditions

Atopic DermatitisHealthyInsulin ResistanceInsulin SensitivityNormal WeightObesityOverweight and ObesityRheumatoid Arthritis

Phase 1

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

CompletedNCT02220153

UCB CelltechHealthy

Start: 2014-07-31End: 2015-09-30Updated: 2015-10-05

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

CompletedNCT04643457

UCB Biopharma SRLAtopic Dermatitis

Start: 2020-11-27End: 2024-06-06Updated: 2025-09-30

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

CompletedNCT05496738

PfizerHealthy

Start: 2022-08-16End: 2024-05-06Updated: 2024-06-06

Phase 2

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

CompletedNCT02654223

Inmunotek S.L.Rhinitis, Rhinoconjunctivitis

Start: 2015-12-30End: 2021-11-30Updated: 2022-01-27

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

NCT02661854

Inmunotek S.L.Rhinitis, Rhinoconjunctivitis

Start: 2016-06-21End: 2020-07-31Updated: 2020-03-11

Phase 3

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

CompletedNCT01768572

SanofiRheumatoid Arthritis

Start: 2013-03-31End: 2014-10-31Updated: 2017-06-26

Unknown Phase

Leptin in Human Energy and Neuroendocrine Homeostasis

TerminatedNCT00265980

Columbia UniversityObesity, Weight Loss

Start: 2002-07-31End: 2013-07-31Updated: 2019-09-18

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

RecruitingNCT06487832

University Hospital TuebingenInsulin Resistance, Insulin Sensitivity, Normal Weight +1

Start: 2024-07-01End: 2027-12-31Target: 60Updated: 2025-03-30

Frontiers in Immunology2024-06-2611 citations

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

Lara D. Veeken2023-02-0211 citations

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

Rheumatology and Therapy2021-09-1423 citations

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.

2020-11-20113 citations

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

ACR Open Rheumatology2020-11-0119 citations

Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.

2020-11-014 citations

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

CPT Pharmacometrics & Systems Pharmacology2020-05-269 citations

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis

Lara D. Veeken2018-11-22123 citations

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

mAbs2018-08-21110 citations

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

2017-12-0712 citations

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Science Translational Medicine2017-11-01195 citations